Our firm--which, through its partner Gerald Meunier as Co-Liaison Counsel, had a leadership role on behalf of plaintiffs--is pleased to announce that the makers of the popular blood-thinner Xarelto® have agreed to a $775,000,000 settlement to resolve litigation by patients who suffered bleeding injuries after taking the prescription drug.
Adverse event reporting of injuries is of monumental value and importance for drugs approved by the FDA. These reports are the basis for modifications and even additions of new or supplemental warnings after drugs have been approved by the FDA and placed on the market.
A Philadelphia jury recently awarded $2.5 million in damages to a 20-year old man who developed gynecomastia (enhancement of male breasts) after taking the prescription drug risperdal. The jury found that Janssen, a subsidiary of Johnson & Johnson, failed to adequately warn users of this side-effect of the drug. The plaintiff was represented at trial by the Philadelphia firm of Kline & Specter, PC. If you or someone you know has experienced side effects from taking risperdal, Gainsburgh Benjamin's products liability attorneys are available for an initial case screening.